About-cancer/treatment/drugs/caplacizumab-yhdp/zh

卡帕珠单抗

本页包含有关caplacizumab-yhdp的简要信息，以及一些链接，这些链接指向有关该药物的用途，研究结果和正在进行的临床试验的更多信息。

美国品牌名称

卡布利维

FDA批准

Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Caplacizumab-yhdp is approved to treat:

• Acquired thrombotic thrombocytopenic purpura (aTTP) in adults. It is used with plasma exchange and immunosuppressive therapy.

More About Caplacizumab-yhdp

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Clinical Trials Accepting Patients

Find Clinical Trials for Caplacizumab-yhdp - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.